Experimental COVID-19 drug shows promise in small pilot trial
NCT ID NCT04534673
First seen May 09, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tested whether adding pegylated interferon lambda to standard care helps hospitalized COVID-19 patients recover faster. Nine adults with mild to moderate symptoms were randomly assigned to receive either the drug plus standard care or standard care alone. The main goals were to measure how long the virus stays in the body and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Soroka UMC
Beersheba, Israel
Conditions
Explore the condition pages connected to this study.